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Considerable debate exists about the optimal treatment of ductal carcinoma in situ (DCIS). Using electronic data
sources, we examined first course treatment patterns among women aged 18 years and older diagnosed with DCIS
between 2000–2010 from six Kaiser Permanente (KP) regions. We calculated the proportion of patients receiving breast
conserving surgery (BCS), BCS plus radiation therapy, unilateral mastectomy, bilateral mastectomy, and hormone therapy.
Multinomial logistic regression was used to assess the association between patient characteristics and treatment. We
included 9,437 women: 1,086 (11.5%) African-American; 1,455 (15.4%) Asian; 918 (9.7%) Hispanic; and 5,978 (63.3%)
non-Hispanic white. Most cases (42.2%) received BCS plus radiation as their initial treatment. Nearly equal numbers
of women received BCS without radiation (28.5%) or unilateral mastectomy (24.6%). Use of bilateral mastectomy was
uncommon (4.7%), and most women (72.2%) did not receive hormone therapy has part of their first course treatment.
We observed statistically significant differences in treatment patterns for DCIS by KP region and patient age. Predictably,
nuclear grade and the presence of comorbidities were associated with first course treatment for DCIS. We observed
statistically significant increases in BCS plus radiation therapy and bilateral mastectomy over time. Although still
uncommon, the frequency of bilateral mastectomy increased from 2.7% in 2000 to 7.0% in 2010. We also observed
differences in treatment by race/ethnicity. Our findings help illustrate the complex nature of DCIS treatment in the
United States, and highlight the need for evidence based guidelines for DCIS care.
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Ductal carcinoma in situ (DCIS) describes breast lesions
characterized by proliferation of abnormal epithelial cells
with an intact basement membrane and no evidence of
stromal invasion. While the age-adjusted incidence of
invasive breast cancer remained relatively stable in the
1980s and 1990s, the incidence of a DCIS diagnosis rose
rapidly, largely as a result of increased mammography
screening (American Cancer Society 2014; Virnig et al.
2010). Since 1999, the rates have stabilized in women age
50 and older but have continued to increase in younger
women. It is estimated that about 22% of all new breast
cancers in 2013 were DCIS (Siegel et al. 2013).
DCIS is non-fatal; however, it is considered to be a
precursor to invasive cancer and it is unclear which
women will develop invasive cancer (Jackson et al. 2008).* Correspondence: heather.s.feigelson@kp.org
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in any medium, provided the original work is pConsiderable debate exists about the optimal treatment
for DCIS, and many have expressed concern that DCIS
is over diagnosed and over treated. The 2009 National
Institutes of Health State of the Science Conference even
recommended that “strong consideration should be given
to elimination of the use of the anxiety-producing term
‘carcinoma’ from the description of DCIS” (Allegra et al.
2010). This has led some to suggest that it may be more
appropriate to adopt a prophylactic approach to managing
patients who present with DCIS, similar to the approach
for managing patients with lobular carcinoma in situ of
the breast (Punglia et al. 2013). Prophylactic treatment of
DCIS after excision would aim to decrease the risk of
development of invasive cancer, rather than to eradicate
residual disease or reduce recurrence.
Given the frequency of a DCIS diagnosis, and the
debate about how to best manage these cases, it is not
surprising that many treatment options are available
for women diagnosed with DCIS. Using the Kaiseris an Open Access article distributed under the terms of the Creative Commons
g/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction
roperly credited.
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we examined first course treatment patterns among women
diagnosed with DCIS from January 1, 2000 through
December 31, 2010 across six KP regions: Colorado,
Georgia, Hawaii, Northern California, Northwest, and
Southern California. The purpose of this analysis was
to describe DCIS treatment across these community
based health plans and over time and to identify factors
that may influence treatment decisions.
Methods
Data sources
The primary data source for this study was the KP
Center for Effectiveness and Safety Research Virtual
Data Warehouse (VDW). As described previously, the
VDW includes standardized variables derived from
administrative databases at each KP site (Ross et al. 2014;
Ritzwoller et al. 2013; Hornbrook et al. 2005). Within the
VDW, the Virtual Tumor Registry (VTR) contains data
consistent with the North American Association of Central
Cancer Registries standards (North American Association
of Central Cancer Registries 2014). VTR data are derived
from manual reviews of cancer patients’ medical charts
by trained abstractors. VTR variables include date of
diagnosis, first-course definitive treatment (surgery, radio-
therapy, chemotherapy, and hormone therapy), tumor
characteristics, and patient demographic characteristics.
VDW diagnosis and procedure files include coded diag-
noses and procedures associated with inpatient and
outpatient encounters or events that were extracted
from electronic medical records and other claims databases.
Codes are based on International Classification of Diseases,
9th Revision, Clinical Modification (ICD-9-CM), Health-
care Common Procedure Coding System (HCPCS), and
the Fourth Edition of the Common Procedure Terminology
codes (CPT-4). This study was approved by the Institu-
tional Review Boards of the six participating health plans.
Study population
All women in the VTR aged ≥ 18 years diagnosed with
DCIS from 01/01/2000 through 12/31/2010 were identi-
fied. The study sample was limited to women for whom
this was their first cancer diagnosis (since history of
cancer may affect treatment decisions for the current
DCIS diagnosis), did not have a simultaneous diagnosis
of an invasive breast cancer (defined as an invasive cancer
diagnosed with 30 days of the DCIS diagnosis), and were
enrolled in the health plan for at least 12 months before
and after the DCIS diagnosis.
Patient characteristics of interest including age at DCIS
diagnosis, year of DCIS diagnosis, nuclear grade of tumor,
and race/ethnicity (White, African American, Hispanic,
Asian, Other/Unknown) were collected from the VTR for
each eligible woman. As an indicator of general health, weused the Quan adaptation of the Charlson Comorbidity
Index modified to exclude cancer diagnoses (Quan et al.
2005) derived from diagnosis codes captured from all hos-
pital and ambulatory encounters that occurred 12 months
prior to DCIS diagnosis. Surrogate patient-level measure
of socioeconomic status was obtained from VDW 2000
Census files by mapping median education level of census
track to patient address.Statistical analysis
We calculated the proportion of patients receiving any
of the following treatments: breast conserving surgery
(BCS), unilateral mastectomy, bilateral mastectomy, BCS
plus radiation therapy, and hormone therapy as defined
through the VTR first course therapy variables (typically
the first six months post diagnosis). Women with no record
of surgery, hormone therapy or radiotherapy were classified
as having received no treatment.
Differences in the distribution of baseline characteristics
between women receiving the different treatments of
interest were evaluated using the Wilcoxon rank-sum test
for interval-level data and the chi-square test for nominal/
ordinal level data. Multinomial logistic regression was
used to assess the association between treatment course
and the following list of predictors: KP region, year of
diagnosis (as a continuous variable), nuclear grade (low/
intermediate, high, or unknown), patient age at diagnosis
(<50 years, 50 – 59 years, 60 – 69 years, and 70 or more
years of age), 2000 census level median education, comor-
bidity status, and race/ethnicity. Customary residual and
influential statistics were examined to assess model fit and
overly influential covariate patterns. All analyses were
performed using SAS 9.2 (SAS Software Inc., Cary, NC).Results
A total of 13,827 women 18 years of age or older were
diagnosed with DCIS (with no simultaneous diagnosis
of invasive cancer) across the six KP regions from
2000–2010. We excluded 262 women who had a prior
diagnosis of DCIS, 1838 women who did not meet our
inclusion criteria of KP membership 12 months before and
after diagnosis, and 1878 women who had a prior diag-
nosis of other cancer. We excluded 70 women because
their reported treatment was not consistent with DCIS
(e.g., chemotherapy); these women could have progressed
to invasive disease or developed another cancer during the
year following diagnosis of DCIS. It is also possible that
these data were in error, or that their treatment was incor-
rectly recorded. We also excluded 32 women whose first
course of therapy data were missing and 138 women who
did not receive any treatment. Finally, we excluded 172
women for whom we could not identify their race/ethni-
city. Our final dataset included 9,437 women.
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study population. Our data set includes 1086 (11.5%)
African-American women, 1455 (15.4%) Asian women
(including Hawaiian and Pacific Islanders), 918 (9.7%)
Hispanic women, and 5978 (63.3%) non-Hispanic white
women. This distribution reflects the underlying popu-
lation for the KP regions combined. Most cases were
diagnosed between 50–69 years of age (59.0%). The
Charlson co-morbidity index, an indicator of prevalent
co-morbid conditions, suggests a relatively healthy popu-
lation at the time of diagnosis: approximately 91% of cases
had 0 or 1 concurrent chronic conditions in the year priorTable 1 Characteristic of DCIS patient population from six














<50 years 1978 21.0
50 – 59 years 2917 30.9
60 – 69 years 2651 28.1









First course surgical therapy
Breast conserving surgery (BCS) 2689 28.5
BCS + radiation 3978 42.2
Bilateral mastectomy 448 4.7




*Receipt of hormone therapy in addition to surgical treatment.to diagnosis. Fifty percent of the tumors were classified
as low or intermediate nuclear grade, 40% were high
nuclear grade, and for 11% of cases these data were
unavailable. Most cases (42.2%) received BCS plus radi-
ation as their initial treatment. Nearly equal numbers
of women received BCS without radiation (28.5%) or
unilateral mastectomy (24.6%). Bilateral mastectomy was
relatively uncommon as first course treatment (4.7%), and
most women (72.2%) did not receive hormone therapy
has part of their first course treatment.
We observed regional variation for receipt of BCS, BCS
plus radiation, and bilateral mastectomy as first course
therapy for DCIS (Figure 1). The fraction of BCS without
radiation therapy ranged between 13-34% (p < 0.001),
and BCS plus radiation therapy ranged between 36-59%
(p < 0.001). Bilateral mastectomy was rare at all sites,
and ranged between <1 - 8% (p < 0.001). We did not
observe statistically significant variation by region for
unilateral mastectomy (p = 0.14) or hormone therapy
(p = 0.06) across regions.
We also observed variation in treatment by age (Figure 2).
For example, BCS with radiation therapy was the most
common treatment among women under age 70 (range
40% - 47%) and BCS without radiation therapy was the
most common treatment (40%) among women 70 years
and older. Frequency of bilateral mastectomy decreased
steadily with increasing age; 9% of women under 50 years
received bilateral mastectomy, compared to only 1% of
women aged 70 years or older. Frequency of unilateral
mastectomy was relatively constant across age groups, and
receipt of adjuvant hormone therapy was highest (35%)
among women aged 50–59 years.
Table 2 shows the results of multinomial logistic regres-
sion for predictors of surgical and radiation treatments,
using BCS only as the referent group. The variation in
treatment by site observed in Figure 1 remained statisti-
cally significant in the multinomial model for all surgical
options. Age, Hispanic ethnicity, nuclear grade, comor-
bidity index and year of diagnosis were also statistically
significant predictors of BCS plus radiation therapy com-
pared to BCS alone. Women aged 70 and older were half
as likely to have BCS plus radiation therapy (OR: 0.54,
95% CI: 0.45-0.63, p < .0001), while women of Hispanic
ethnicity were 30% more likely to have BCS plus radiation
therapy (OR:1.30, 95% CI: 1.08-1.56, p = 0.005). Women
with high nuclear grade tumors were twice as likely to
have adjuvant radiation therapy (OR: 2.01, 95% CI:
1.80-2.25, p < 0.0001), and women with two or more
comorbidities were less likely to have BCS plus radi-
ation therapy compared to BCS alone (OR: 0.75, 95%
CI: 0.62-0.89, p = 0.002). Likelihood of BCS plus radi-
ation therapy also increased over time (OR: 1.06 per
year, 95% CI: 1.04-1.08, p < 0.0001) compared to BCS
alone.
Figure 1 First course therapy by Kaiser Permanente region. Each region is represented by a different colored bar, as indicated in the legend;
all regions combined shown on the right most bar for each type of treatment. P-values shown for chi-squared test for differences across regions.
The “any hormone treatment” group is not mutually exclusive, as patients may also be represented in one of the surgical treatment groups.
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tomy compared to BCS alone included age, race/ethnicity,
education, and tumor grade (Table 2). Compared to the
pattern observed for BCS alone, women 50 years of age or
older were less likely than women less than 50 years of age
to receive unilateral mastectomy, and compared to whites,
Asian women were more likely to have unilateral mastec-
tomy (OR: 1.62, 95% CI: 1.37-1.91, p < 0.0001). Women
with high nuclear grade tumors compared to low or inter-
mediate nuclear grade were more than twice as likely to
receive unilateral mastectomy (OR: 2.70, 95% CI: 2.39-3.06,
p < 0.0001). Similarly, women with bilateral mastectomy
had many of the same statistically significant predictors asFigure 2 First course therapy by age group. Each treatment type is rep
“any hormone treatment” group is not mutually exclusive, as patients maythose who underwent unilateral mastectomy including age,
race/ethnicity, and tumor grade. However, women of Asian
ethnicity were less likely to have bilateral mastectomy
compared to white women (OR: 0.52, 95% CI: 0.36-0.76,
p = 0.0007). African-American women were also less likely
to have bilateral mastectomy (OR: 0.56, 95% CI: 0.39-0.80,
p = 0.0014). Likelihood of bilateral mastectomy increased
over time compared to BCS (OR: 1.16 per year, 95% CI:
1.12-1.20, p < 0.0001). Although still uncommon, the frac-
tion who underwent bilateral mastectomy increased from
2.7% in 2000 to 7.0% in 2010 (data not shown).
Table 3 compares women with and without adjuvant
hormone therapy (initiated in the first six months afterresented by a different colored bar, as indicated in the legend. The
also be represented in one of the surgical treatment groups.
Table 2 Odds ratios and 95% confidence intervals from multinomial logistic regression models comparing first course
therapy groups with breast conserving surgery (BCS) as referent group







1 1.0 1.20 (0.97-1.49) 1.16 (0.91-1.48) 2.76 (1.88-4.04)
2 1.0 2.10 (1.47-2.99) 2.19 (1.49-3.22) 3.69 (2.07-6.59)
3 1.0 1.31 (0.96-1.78) 0.75 (0.52-1.08) 0.32 (0.08-1.33)
4 [Referent] [Referent] [Referent]
5 1.0 3.00 (2.24-4.02) 1.93 (1.39-2.70) 4.59 (2.87-7.34)
6 1.0 0.62 (0.56-0.70) 0.75 (0.66-0.85) 1.39 (1.09-1.78)
Age at diagnosis
<50 years [Referent] [Referent] [Referent]
50-59 years 1.0 1.12 (0.96-1.30) 0.79 (0.67-0.93) 0.54 (0.42-0.70)
60-69 years 1.0 0.98 (0.84-1.14) 0.69 (0.59-0.82) 0.29 (0.22-0.39)
70+ years 1.0 0.54 (0.45-0.63) 0.55 (0.46-0.65) 0.08 (0.05-0.13)
Race/Ethnicity
White [Referent] [Referent] [Referent]
African American 1.0 0.88 (0.74-1.04) 0.91 (0.75-1.10) 0.56 (0.39-0.80)
Asian 1.0 1.11 (0.95-1.30) 1.62 (1.37-1.91) 0.52 (0.36-0.76)
Hispanic 1.0 1.30 (1.08-1.56) 1.16 (0.94-1.42) 0.69 (0.48-1.00)
Census Tract % College Educated (Quintiles)
1: 32.3% - 78.8% 1.0 1.11 (0.94-1.30) 0.99 (0.83-1.19) 1.06 (0.78-1.46)
2: 78.9% - 86.3% 1.0 1.06 (0.90-1.24) 0.77 (0.64-0.92) 0.78 (0.56-1.08)
3: 86.5% - 92.2% 1.0 1.05 (0.89-1.24) 0.88 (0.73-1.05) 0.82 (0.59-1.14)
4: 92.3% - 95.7% 1.0 1.00 (0.84-1.18) 0.76 (0.63-0.92) 0.75 (0.53-1.05)
5 (highest): > 95.7% [Referent] [Referent] [Referent]
Year of Diagnosis 1.0 1.06 (1.04-1.08) 1.00 (0.99-1.02) 1.16 (1.12-1.20)
Comorbidity Index
0 [Referent] [Referent] [Referent]
1 1.0 0.84 (0.73-0.96) 1.01 (0.87-1.18) 0.88 (0.66-1.17)
2+ 1.0 0.75 (0.62-0.89) 0.95 (0.78-1.16) 0.81 (0.53-1.23)
Nuclear Grade
Low/Intermediate [Referent] [Referent] [Referent]
High 1.0 2.01 (1.80-2.25) 2.70 (2.39-3.06) 2.52 (2.03-3.14)
Unknown 1.0 0.93 (0.79-1.10) 1.16 (0.96-1.40) 1.07 (0.73-1.57)
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they received. Unlike the surgical and radiotherapy treat-
ments, there was little variation by KP region in the use
of hormone therapy. Hormone therapy use declined by
age; women aged 60 years and over were less likely than
younger women to receive hormone therapy. For women
aged 70 years or over, the OR = 0.65 (95% CI: 0.56-0.76,
p < .0001) for receipt of hormone therapy compared to
women < 50 years of age. African-American women were
less likely than white women to receive hormone therapy
(OR = 0.82, 95% CI: 0.70-0.96, p = 0.014), while Hispanic
(OR = 1.20, 95%CI: 1.02-1.40, p = 0.03) and Asian (OR =1.18, 95% CI: 1.03-1.34, p = 0.02) women were more likely
than white women to receive hormone therapy. Women
with two or more comorbidities were less likely to receive
hormone therapy (OR = 0.76, 95% CI: 0.64-0.91, p = 0.003),
as were women with high nuclear grade or undifferenti-
ated tumors compared to those with low or intermedi-
ate nuclear grade tumors (OR = 0.83, 95% CI: 0.76-0.92,
p = 0.0002).
Discussion
We observed statistically significant differences in treat-
ment patterns for DCIS by both KP region and patient
Table 3 Odds ratios and 95% confidence intervals from
logistic regression model comparing women who
received hormone therapy (in addition to surgical
therapy) to women who received no hormone therapy
No hormone




1 1.0 1.29 (1.08-1.55)
2 1.0 1.21 (0.93-1.58)
3 1.0 1.14 (0.87-1.49)
4 Referent
5 1.0 0.96 (0.78-1.19)
6 1.0 0.97 (0.87-1.07)
Age at diagnosis
< 50 years Referent
50-59 years 1.0 1.11 (0.98-1.25)
60-69 years 1.0 0.88 (0.77-1.00)
70+ years 1.0 0.65 (0.56-0.76)
Race/Ethnicity
White Referent
African American 1.0 0.82 (0.70-0.96)
Asian 1.0 1.18 (1.03-1.34)
Hispanic 1.0 1.20 (1.02-1.40)
Census Tract % College
Educated (Quintiles)
1: 32.3% - 78.8% 1.0 1.03 (0.89-1.18)
2: 78.9% - 86.3% 1.0 1.02 (0.88-1.18)
3: 86.5% - 92.2% 1.0 0.96 (0.83-1.11)
4: 92.3% - 95.7% 1.0 0.81 (0.69-0.94)
5 (highest): > 95.7% Referent
Year of Diagnosis 1.0 0.99 (0.97-1.00)
Comorbidity Index
0 Referent
1 1.0 1.22 (1.09-1.38)
2+ 1.0 0.76 (0.64-0.91)
Nuclear Grade
Low/Intermediate Referent
High 1.0 0.83 (0.76-0.92)
Unknown 1.0 0.89 (0.77-1.05)
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presence of comorbidities were associated with first
course treatment for DCIS. Because we have large numbers
of patients from several racial/ethnic groups, we were able
to demonstrate differences in treatment by race/ethnicity.
We also observed increases in BCS plus radiation therapy
and bilateral mastectomy over time.
Our population’s patterns of treatment with surgery and
radiation therapy are similar to those of Liu et al. (2014),who used treatment data from the SEER 18 Registries
database, and to Haque et al. (2010), who examined 3000
DCIS cases diagnosed between 1990–2001 in three inte-
grated health plans, two of which were KP locations and
included in the current study. Nearly 30% of our patient
population were treated with adjuvant hormone agents,
which is higher than reported in previous studies (Jackson
et al. 2008; Haque et al. 2010; Habel et al. 2009). The
increased use of hormone therapy in our study popula-
tion, who were diagnosed 2001–2010, may be attributed
to the clinical trials data that emerged post 2000 that
demonstrated tamoxifen’s efficacy in reducing subsequent
breast cancer among DCIS patients (Fisher et al. 2001).
Haque et al. (2010), observed no statistically significant
differences in adjuvant treatments (radiation therapy
and/or hormone therapy) by race/ethnicity; however, we
observed several differences in first course treatment by
race/ethnicity. Asian women were less likely to have bilat-
eral mastectomy (OR= 0.52, 95% CI: 0.36-0.76, p = 0.0007),
and more likely to have unilateral mastectomy (OR = 1.62,
95% CI: 1.37-1.91, p < 0.0001) than white women. African-
American women were also less likely to have bilateral
mastectomy (OR= 0.56, 95% CI: 0.39-0.80, p = 0.0014)
compared to white women. For hormone therapy, Asian
and Hispanic women were both more likely to receive
hormone therapy, while African American women were
less likely to receive hormone therapy compared to white
women. It is possible that the proportion of African-
American women receiving hormone therapy was lower
than white women because African-American women are
more likely than white women to have tumors that are
estrogen receptor negative (Liu et al. 2014; Howlader et al.
2014). However, receptor status was not reliably captured
for our DCIS cases until recently, and thus we could
not include receptor status in our analysis. Women with
high nuclear grade tumors were also less likely to receive
hormone therapy compared to those with low or inter-
mediate grade tumors (OR = 0.83, 95% CI: 0.76-0.92). It is
possible that high nuclear grade tumors are also less likely
to be estrogen receptor positive, which could explain this
association, but we cannot examine this in our data.
The strengths of our study include its geographic vari-
ation, large size and racial/ethnic diversity. Our study
included over 1,000 African American women, over 900
Hispanic women, and nearly 1,400 Asian women. We
have previously demonstrated that the VDW is highly
accurate for the report of chemotherapy (Delate et al.
2012); however, the accuracy of radiation therapy is less
clear. Other limitations of our study include lack of
information on family history, genetic testing, and patient
or physician concerns that certainly influence treatment
decisions (Arvold et al. 2011; Courdi et al. 2010; Field
et al. 2011; Fisher et al. 2012). Further, because we relied
on electronic data that were available at all the
Feigelson et al. SpringerPlus  (2015) 4:24 Page 7 of 8participating sites over a 10-year period, we are missing
information on tumor characteristics not available at all
sites, such as size and histology, which also predict
treatment choice (Virnig et al. 2010; Silverstein & Lagios
2010; Schmale et al. 2012). Nonetheless, our results are
valuable in describing current treatment patterns in the
community setting that likely can be generalized beyond
Kaiser Permanente.
Our findings help illustrate the complex nature of
DCIS treatment in the United States. Our observation of
treatment differences, even among regions of the same
integrated health care system, is not surprising, given
that no current consensus exists on how best to treat
DCIS (Allegra et al. 2010; Punglia et al. 2013; Greenberg
et al. 2014), and treatment decisions are influenced by
patient or physician preference (Morrow et al. 2009), as
well as other factors such as distance to radiation therapy
facilities. Randomized trials and observational studies have
shown that adjuvant radiation therapy reduces the risk
of a second ipsilateral event compared to BCS alone
(Greenberg et al. 2014). However, there is no evidence
that BCS alone results in poorer survival compared to
BCS plus radiation therapy, even in the presence of
adverse prognostic factors (Virnig et al. 2010). Until we
have better clinical or molecular markers to indicate
which DCIS patients are most likely to have a subsequent
cancer, defining the “best” treatment for an individual
woman will remain a challenge.Competing interests
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